CytoSorbents Corporation

11/19/2026 | Press release | Distributed by Public on 11/19/2026 06:01

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Notes Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, or this Report, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue," negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms "CytoSorbents," "Company," "we," "us" and "our" refer to CytoSorbents Corporation.

From time to time, forward-looking statements also are included in our other periodic reports on Forms 10-K and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable Report or public statement. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report or public statement and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise. For discussion of factors that we believe could cause our actual results to differ materially from expected and historical results see "Item 1A - Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

Overview

We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, extracorporeal membrane oxygenation or ECMO, and heart-lung machines). CytoSorbents' technologies are used in a number of broad applications. Specifically, four important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death, 3) the removal of liver toxins that accumulate in acute liver dysfunction or failure and 4) the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in more than 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA EUA in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.

​

In the United States and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two United States Food and Drug Administration ("FDA") Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.

The Company continues to actively pursue regulatory approval of DrugSorb-ATR with the FDA and expects to pursue regulatory approval in Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued United States and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap™ and others. While not our primary means of communication, investors can learn more about us by visiting our social media channels. We encourage investors, the media, and others interested in us to review the information posted on our Facebook site and our X account, where investors, the media, and other interested parties can subscribe. The information contained in our social media accounts is not incorporated by reference into this Quarterly Report on Form 10-Q or other documents we file with or furnish to, the SEC.

Upon approval, the Company expects to rapidly commercialize DrugSorb-ATR in the United States and Canada to address this large unmet medical need, with an initial estimated total addressable market of $300 million today to over $1 billion over time as we pursue additional indications for DrugSorb-ATR to remove additional classes of blood thinners and expansion of the antithrombotic removal application beyond cardiac surgery and across other surgical specialties. We believe that DrugSorb-ATR has the potential to become an "all-in-one" countermeasure for these agents.

DrugSorb-ATR® for Brilinta®

In August 2025, we received the FDA's decision on our appeal of the original DrugSorb-ATR application. Importantly, the FDA identified no concerns regarding device safety but upheld the prior denial of the application and requested additional analysis of real-world evidence to support the proposed indication for reducing the severity of perioperative bleeding in patients undergoing CABG surgery while on Brilinta® (ticagrelor, AstraZeneca).

Following the appeal decision and based upon feedback from FDA, we announced our intention to submit a new De Novo application incorporating additional supporting information, primarily based on real-world evidence and clinical outcomes generated through routine clinical use of the device. As part of this process, we held a formal pre-submission meeting with the FDA in January 2026 where the FDA outlined that additional information should include new mechanistic data in addition to the real-world evidence and clinical outcomes generated through routine clinical use of the device ex-US. We held another pre-submission meeting in August 2026 to discuss options to generate this additional mechanistic data. Next, we expect to finalize the testing protocol, which will require FDA review and approval and possibly another pre-submission meeting. Once the protocol is approved by FDA, we anticipate completing the required testing and submitting a new De Novo application in 2027. Following submission, a regulatory decision would generally be expected within the FDA's targeted 150-day MDUFA review timeline, although the actual review period may be shorter or longer depending on the nature and extent of interactive review questions from the FDA.

DrugSorb-ATR® for DOACs: Eliquis® and Xarelto®

In August 2026, we held a pre-submission meeting with FDA to discuss available removal data for DOACs (direct oral anticoagulants) such as apixaban (Eliquis, Pfizer/BMS) and rivaroxaban (Xarelto,Bayer/Janssen), the market leading DOACs, from benchtop and in-vivo testing with real-world use during urgent cardiac surgery and determine what, if any, additional information may be required to support a parallel De Novo submission for DOAC removal during cardiac surgery. We continue to engage with FDA in interactive discussions to clarify the information that will be required for an upcoming De Novo submission and anticipate reaching alignment during a follow-up pre-submission meeting with FDA soon. We anticipate submitting a De Novo application for DOAC removal in 2027. Globally, tens of millions of patients are on chronic or life-long DOAC therapy due to atrial fibrillation, deep vein thrombosis, pulmonary embolism, peripheral vascular disease, or post-surgical prophylaxis. An estimated 5-10% of emergent cardiac surgery cases involve patients who are currently therapeutic on a DOAC and risk serious or life-threatening bleeding.

​

Our executive offices are located at 305 College Road East, Princeton, New Jersey 08540, and our telephone number is (732) 329-8885. Our website address is http://www.cytosorbents.com. We make available free of charge through our website our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material, or furnish it to the SEC. We also similarly make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. We have included our website address as an inactive textual reference only. The information contained on or accessible through our corporate website is not incorporated by reference in this Quarterly Report on Form 10-Q and should not be considered part of this report.

Summary of Operational and Recent Business Highlights

● Total revenue was $28.2 million for the nine months ended September 30, 2026, an increase of $0.4 million, or 1.4%, compared to the prior year. For the three months ended September 30, 2026, total revenue was $9.7 million, an increase of 2.6%.
● Gross profit was $20.5 million for the nine months ended September 30, 2026, an increase of $0.8 million, or 4.2%, compared to the prior year. Gross margin was 73% for the nine months ended September 30, 2026, compared to 70.7% in the prior year. Gross profit for the three months ended September 30, 2026, was $7.3 million, an increase of $0.7 million or 9.9% compared to the prior year. Gross margin was 75.3% for the three months ended September 30, 2026, compared to 70.3% in the prior year.
● Our loss from operations improved by approximately $3.6 million, or 33.9%, to $6.9 million for the nine months ended September 30, 2026, compared to $10.4 million for the nine months ended September 30, 2025. For the three months ended September 30, 2026 and 2025, our loss from operations improved by approximately $1.7 million, or 59.3%, to $1.2 million from $2.9 million, respectively. These improvements were the result of our Strategic Workforce and Cost Reduction program, and other efforts over the past year to lower costs, drive efficiencies and bring the Company to operating cash flow breakeven in the second half of 2026.
● Our total change in cash decreased to $0.2 million for the third quarter and $2.0 million for the nine months ended September 30, 2026, compared to $2.7 million and $7.5 million for the three and nine months ended September 30, 2025, respectively. Excluding restructuring payments of $0.25 million, and $0.79 million for the three and nine months ended September 30, 2026, the Company would have generated positive cash flow of approximately $43,000, and cash burn of $1.2 million for the three and nine months ended September 30, 2026. The improvement in cash burn is primarily due to improved operating margins and the impact of our strategic workforce and cost reduction plan as well as improved management of inventory and working capital.
● The U.S. and Canadian pivotal STAR-T randomized, controlled trial results have now been published in the Journal of Thoracic and Cardiovascular Surgery (2026) - the leading peer-reviewed cardiothoracic surgery journal in the U.S. The authors summarized the results in the graphical abstract and concluded in the central message of the article that, "Intraoperative DrugSorb-ATR use for ticagrelor removal is safe and can reduce the severity of bleeding after isolated CABG in patients operated within 2 days of drug discontinuation."
● New real-world data from an independent, patient-level matched analysis of 587 patients undergoing urgent coronary artery bypass grafting (CABG) surgery after recent ticagrelor exposure, presented at the European Society of Cardiology (ESC) Congress 2026 and announced by the Company on September 2, 2026, demonstrated that intraoperative use of CytoSorb was associated with a statistically significant 37% relative reduction in severe (BARC-4) bleeding (21.8% vs. 34.5%; p=0.002), resulting in a clinically meaningful NNT (Number Needed to Treat) of 8 patients treated with our device to prevent 1 major bleed, consisted with the NNT of 6 seen in the STAR-T pivotal trial. Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also observed, with no serious device-related events reported. These findings are consistent with the results of the STAR-T randomized controlled trial and are expected to form a core component of the additional clinical evidence for a new De Novo submission for DrugSorb-ATR, which, following recent Pre-Submission meeting with the U.S. FDA, the Company expects to file in early 2027.

​

● Key data presentations from multiple real-world data analyses from the Company-sponsored STAR (Safe and Timely Antithrombotic Removal) blood thinner and COSMOS (CytoSorb treatment Of critically ill patientS) critical care registries were presented at two major European medical congresses including EACTS (European Association for Cardio-Thoracic Surgery) 2026 and the ESICM (European Society of Intensive Care Medicine) LIVE 2026 conferences in October. At EACTS, the focus was on cardiac surgery including the use of CytoSorb to reduce anti-thrombotic related CABG bleeding, treatment of post-operative vasoplegia, and improving heart transplant. At ESICM, data were presented on the use of CytoSorb in liver support, ECMO and hyperinflammation, and treatment insights from the first 200 patients of the COSMOS registry with sepsis and septic shock.

Results of Operations:

Comparison for the three months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Three Months Ended September 30,

​

​

2026

​

2025

​

​

(unaudited)

​

(unaudited)

​

​

​

​

​

% of

​

​

​

% of

​

​ ​ ​

Amount

​ ​ ​

Revenue

​ ​ ​

Amount

​ ​ ​

Revenue

​

​ ​ ​

(in thousands)

​ ​ ​

​

​ ​ ​

(in thousands)

​ ​ ​

​

Revenue

​

$

9,728

​

100

%

$

9,485

​

100

%

Cost of goods sold

​

2,400

​

24.7

%

​

2,819

​

29.7

%

Gross profit

​

7,328

​

75.3

%

​

6,666

​

70.3

%

Operating expenses:

​

​

​

​

​

​

​

​

​

​

Research and development

​

1,145

​

11.8

%

​

918

​

9.7

%

Selling, general and administrative

​

7,102

​

73.0

%

​

8,610

​

90.8

%

Restructuring

​

​

250

​

2.6

%

​

-

​

-

​

Total operating expenses

​

8,497

​

87.3

%

​

9,528

​

100.5

%

Loss from operations

​

(1,169)

​

(12.0)

%

​

(2,862)

​

(30.2)

%

Other income (expense):

​

​

​

​

​

​

​

​

​

​

Interest expense, net

​

(892)

​

(9.2)

%

​

(645)

​

(6.8)

%

Gain (loss) on foreign currency transactions

​

7

​

0.1

%

​

(64)

​

(0.7)

%

Total other income (expense), net

​

(885)

​

(9.1)

%

​

(709)

​

(7.5)

%

Loss before income taxes

​

$

(2,054)

​

(21.1)

%

$

(3,571)

​

(37.6)

%

​

Revenues

For the three months ended September 30, 2026, we generated total revenue of approximately $9.7 million, which is in line with revenues for the three months ended September 30, 2025, of $9.5 million. Revenue performance was led by increases in our distributor and strategic partner territories and direct sales outside Germany, but offset by a decline in sales in Germany attributed to a smaller but more focused sales force.

Gross Profit

Gross profit was approximately $7.3 million for the three months ended September 30, 2026, an increase of approximately $0.6 million, or 9.9%, as compared to gross profit of $6.7 million for the three months ended September 30, 2025. Gross margins were 75.3% and 70.3% for the three months ended September 30, 2026 and 2025, respectively. The improvement in gross margins reflects the impact of efforts to rebalance production, lower operating costs, and improve efficiencies.

​

Research and Development Expenses

Research and development costs were approximately $1.1 million and $0.9 million for the three months ended September 30, 2026 and 2025, respectively, an increase of approximately $0.2 million, or 24.7%. This increase was primarily driven by higher other research and development costs of approximately $0.2 million, primarily due to lower grant income and higher product development costs. Clinical costs were approximately $0.7 million for each of the three months ended September 30, 2026 and 2025. Non-cash stock-based compensation included in research and development expenses decreased to less than $0.1 million from approximately $0.1 million in the prior year period, and cash compensation costs were lower as a result of the Strategic Workforce and Cost Reduction Plan.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses were approximately $7.1 million and $8.6 million for the three months ended September 30, 2026 and 2025, respectively, a decrease of approximately $1.5 million, or 17.5%. The decrease is primarily due to decreases in other general and administrative expenses of $1.1 million, legal, financial and consulting expenses of $0.3 million, and stock-based compensation expense of $0.1 million. The decrease in other general and administrative expenses primarily reflects lower compensation costs of approximately $0.5 million as a result of the Strategic Workforce and Cost Reduction Plan, lower selling and travel expenses, including congresses and marketing expenses, of approximately $0.5 million, and a non-cash loss on abandoned patents of approximately $0.2 million recorded in the prior year period.

Gain (Loss) on Foreign Currency Transactions

For the three months ended September 30, 2026, there was a slight gain on foreign currency transactions, as compared to a loss on foreign currency transactions of approximately $0.1 million for the three months ended September 30, 2025. The gain and loss for each of the three months ended September 30, 2026 and 2025 were directly related to changes in the spot exchange rate of the Euro to the U.S. dollar.

Restructuring

During the fourth quarter of 2025 and through the second quarter of fiscal 2026, the Company initiated a strategic workforce and cost reduction plan (the "Strategic Workforce and Cost Reduction Plan") to reduce costs, optimize operations, and accelerate a path to operating cash-flow profitability. Our restructuring expenses were approximately $0.3 million for the three months ended September 30, 2026, primarily related to cash-based severance and related workforce reduction charges. There were no charges for the three months ended September 30, 2025.

Loss From Operations

Our loss from operations improved by 59.3% to approximately $1.2 million for the three months ended September 30, 2026, from approximately $2.9 million for the three months ended September 30, 2025.

​

Comparison for the nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30,

​

​

2026

​

2025

​

​

(unaudited)

​

(unaudited)

​

​

​

​

​

% of

​

​

​

​

% of

​

​

Amount

​

Revenue

​

Amount

​

Revenue

​

​ ​ ​

(in thousands)

​ ​ ​

​

​ ​ ​

(in thousands)

​ ​ ​

​

Revenue

​

$

28,224

100

%

$

27,829

​

100

%

Cost of goods sold

​

7,719

27.3

%

8,142

​

29.3

%

Gross profit

​

20,505

72.7

%

19,687

​

70.7

%

Operating expenses:

​

​

​

​

​

​

​

​

Research and development

​

3,623

12.8

%

3,842

​

13.8

%

Selling, general and administrative

​

23,173

82.1

%

26,209

​

94.2

%

Restructuring

​

​

562

​

2.0

%

​

-

​

-

​

Total operating expenses

​

27,358

96.9

%

30,051

​

108.0

%

Loss from operations

​

(6,853)

(24.3)

%

(10,364)

​

(37.2)

%

Other income (expense):

​

​

​

​

​

​

​

​

Interest expense, net

​

(2,618)

(9.3)

%

(1,866)

​

(6.7)

%

Gain (loss) on foreign currency transactions

​

(2,534)

(9.0)

%

9,128

​

32.8

%

Total other income (expense), net

​

(5,152)

(18.3)

%

7,262

​

26.1

%

Loss before income taxes

​

$

(12,005)

(42.5)

%

$

(3,102)

​

(11.1)

%

​

Revenues

For the nine months ended September 30, 2026, we generated total revenue of approximately $28.2 million, an increase of approximately $0.4 million, or 1.4%, compared to revenues of approximately $27.8 million for the nine months ended September 30, 2025. Revenue growth was led by strength in our distributor and strategic partner territories and direct sales outside Germany, offset by a reduction in sales in Germany. The Company began a proactive reorganization and strategic realignment of our German commercial team and sales approach in 2025 to drive improved sale processes, account targeting and customer engagement. This process has led to a smaller and more focused team in Germany and we remain confident these improvements will lead to stronger execution and improved performance. Meanwhile, we have begun to add back 3-5 additional sales representatives in Germany through early 2027. Changes in foreign currency rates positively impacted revenue by approximately 3.0% compared to the prior year.

Gross Profit

Gross profit was approximately $20.5 million for the nine months ended September 30, 2026, an increase of approximately $0.8 million, or 4.2%, as compared to gross profit of $19.7 million for the nine months ended September 30, 2025. Gross margins were 72.7% and 70.7% for the nine months ended September 30, 2026 and 2025, respectively. The improvement in gross margins reflects the impact of efforts to rebalance production, lower operating costs, and improve efficiencies.

​

Research and Development Expenses

Research and development costs were approximately $3.6 million and $3.8 million for the nine months ended September 30, 2026 and 2025, respectively, a decrease of approximately $0.2 million, or 5.7%. This decrease was primarily driven by lower clinical costs of approximately $0.4 million, reflecting lower clinical trial and study costs and lower compensation costs, partially offset by higher other research and development costs of approximately $0.1 million, primarily due to lower grant income. Non-cash stock-based compensation included in research and development expenses decreased to approximately $0.2 million from approximately $0.3 million in the prior year period.

Restructuring

During the fourth quarter of 2025 and into the second quarter of fiscal 2026, the Company initiated the Strategic Workforce and Cost Reduction Plan to reduce costs, optimize operations, and accelerate a path to cash-flow profitability. Our restructuring expenses were approximately $0.6 million for the nine months ended September 30, 2026, which consisted of cash-based severance and related workforce reduction charges. There were no such charges for the nine months ended September 30, 2025.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses were approximately $23.2 million and $26.2 million for the nine months ended September 30, 2026 and 2025, respectively, representing a decrease of approximately $3.0 million, or 11.6%. The decrease was primarily due to decreases in other general and administrative expenses of $1.8 million, legal, financial and consulting expenses of $0.8 million, and stock-based compensation expense of $0.4 million, partially offset by an increase in royalty expense of less than $0.1 million. The decrease in other general and administrative expenses primarily reflects lower selling and travel expenses, including congresses, and marketing expenses, of approximately $1.1 million, lower compensation costs of approximately $1.0 million, primarily as a result of the Strategic Workforce and Cost Reduction Plan, and lower sales commissions of approximately $0.3 million, partially offset by lower overhead costs allocated to grant-funded programs of approximately $0.4 million and higher bad debt expense of approximately $0.2 million.

Gain (Loss) on Foreign Currency Transactions

For the nine months ended September 30, 2026, the loss on foreign currency transactions was approximately $2.5 million, as compared to a gain on foreign currency transactions of approximately $9.1 million for the nine months ended September 30, 2025. The current year loss was directly related to a decrease in the spot exchange rate of the Euro to the U.S. dollar as of September 30, 2026, to $1.1355 per Euro from $1.1750 per Euro as of December 31, 2025. The prior year gain was directly related to the increase in the spot exchange rate of the Euro to the U.S. dollar as of September 30, 2025 to $1.17 per Euro from $1.03 per Euro at December 31, 2024.

Loss From Operations

Our loss from operations improved by 33.9% to approximately $6.9 million, from $10.4 million for the nine months ended September 30, 2026, and 2025, respectively. This improvement was primarily the result of a 9.0% reduction in operating expenses compared to the prior year, resulting from our efforts to lower costs and improve operating margins and efficiencies including the Company's Strategic Workforce and Cost Reduction Plan, which are all consistent with our goal to achieve operating cash flow breakeven in the second half of 2026.

Liquidity and Capital Resources

Since inception, our operations have been primarily financed through the issuance of debt and equity securities. As of September 30, 2026, we had current assets of approximately $15.4 million and current liabilities of approximately $28.0 million.

​

Net change in cash, cash equivalents and restricted cash

The following summary presents the sources and uses of cash in our operating, investing, and financing activities, and the related effect of exchange rates on cash:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Three Months Ended September 30,

​ ​ ​

Nine Months Ended September 30,

​

​ ​ ​

2026

​ ​ ​

2025

​ ​ ​

Change ($)

​ ​ ​

Change (%)

​ ​ ​

2026

​ ​ ​

2025

​ ​ ​

Change ($)

​ ​ ​

Change (%)

​

​

(amounts, in thousands)

​

(amounts, in thousands)

Net cash used in operating activities

​

$

(268)

​

$

(2,577)

​

$

2,309

​

89.6

%

$

(2,013)

​

$

(7,552)

​

$

5,539

​

73.3

%

Net cash provided by (used in) investing activities

​

$

(4)

​

$

55

​

$

(59)

​

(107.3)

%

$

(43)

​

$

(124)

​

$

81

​

65.3

%

Net cash provided by financing activities

​

$

-

​

$

-

​

$

-

​

-

%

$

-

​

$

6,831

​

$

(6,831)

​

(100.0)

%

Effect of exchange rates on cash

​

$

64

​

$

(146)

​

$

210

​

143.8

%

$

12

​

$

139

​

$

(127)

​

(91.4)

%

Net change in cash, cash equivalents, and restricted cash

​

$

(208)

​

$

(2,668)

​

$

2,460

​

92.2

%

$

(2,044)

​

$

(706)

​

$

(1,338)

​

(189.5)

%

​

Net cash used in operating activities includes restructuring payments of $0.25 million, and $0.79 million for the three and nine months ended September 30, 2026. Excluding these restructuring payments the Company would have generated a positive change in cash of $43,000, and a total cash burn of $1.2 million for the three and nine months ended September 30, 2026. The improvement in cash burn is primarily due to improved operating margins and the impact of our strategic workforce and cost reduction plan, as well as improved inventory and working capital management, which are further discussed in this Management's Discussion and Analysis of Financial Condition and Results of Operations under "Resource Allocation and Path to Cash-Flow Profitability".

Nasdaq Listing Compliance

On October 2, 2025, the Company received notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that it was not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company did not regain compliance during the initial 180-day period ended March 31, 2026, and on April 1, 2026, Nasdaq granted the Company a second 180-day compliance period, until September 28, 2026, to regain compliance with the Minimum Bid Price Requirement in accordance with Nasdaq Listing Rule 5810(c)(3)(A). On September 8, 2026, the Company effected a 1-for-20 reverse stock split of its common stock. Following the Reverse Stock Split, the closing bid price of the Company's common stock remained at or above $1.00 per share for 10 consecutive trading days through September 21, 2026. On September 22, 2026, the Staff notified the Company that it had regained compliance with the Minimum Bid Price Requirement and that the matter was closed.

On June 29, 2026, the Company received a letter from the Staff of Nasdaq notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the Company's Market Value of Listed Securities was less than the $35 million minimum required for continued listing on the Nasdaq Capital Market (the "MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until December 28, 2026, to regain compliance with the MVLS Requirement.

Management's plans with respect to the MVLS Requirement include actively monitoring the market value of the Company's common stock and pursuing potential capital-raising transactions. The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standards, including by increasing its stockholders' equity to at least $2.5 million. There can be no assurance that the Company will regain compliance with the MVLS Requirement, that any actions taken by the Company will result in a sustained increase in the market value of the Company's common stock, or that the Company's common stock will continue to be listed on Nasdaq.

As of the date of issuance of these financial statements, the Company has not regained compliance with the MVLS Requirement. The Company's common stock continues to trade on the Nasdaq Capital Market under the symbol "CTSO." If the Company does not regain compliance by December 28, 2026, Nasdaq will notify the Company that its securities are subject to delisting, and the Company may appeal such determination to a Nasdaq Hearings Panel.

​

Effective Shelf Registration

We have an effective shelf registration statement dated September 30, 2024 with the SEC which enables us to raise up to $150 million in one or more offerings, through the issuance and sale of any combination of equity securities, debt securities, warrants and units. Approximately $149.7 million of this amount was available as of September 30, 2026; however, the use of the Shelf is subject to a limitation of one-third of our public float in any rolling twelve-month period, when our public float is below $75 million, which is referred to as the "baby shelf" rules. We have also allocated $20 million of our total shelf amount to our ATM facility. As of September 30, 2026, approximately $19.4 million was available for use under the ATM facility, subject to certain limitations. During the nine months ended September 30, 2026, we did not raise any proceeds under the ATM facility.

Loan and Security Agreement

On June 28, 2024 (the "Closing Date"), the Company entered into a Loan and Security Agreement with the Avenue Capital Group ("Loan"). Avenue Capital Group agreed to loan the Company up to an aggregate of $20 million (the "Avenue Capital Commitment"), to be disbursed in two tranches. The first tranche of $15.0 million ("Tranche 1"), consisted of $10.0 million which was available to the Company on the Closing Date and $5.0 million constituted restricted cash, which was released from its restriction on January 10, 2025, as the following conditions were achieved: (i) the FDA has accepted the Company's application for review with respect to DrugSorb-ATR De Novo 510(k) and (ii) the Company received a minimum of $3.0 million in net proceeds from the sale of its equity securities after the Closing Date. The restriction was released on a dollar-for-dollar basis for equity raised between $3.0 million and $5.0 million. The second tranche ("Tranche 2") consisted of $5.0 million, which would have been disbursed at the Company's request between July 1, 2025 and December 31, 2025, if the Company received FDA marketing approval of its DrugSorb-ATR application, which it did not. The proceeds from the Avenue Capital Commitment were used to pay off the existing outstanding debt with Bridge Bank and were additionally used for working capital purposes and to fund general business requirements. Amounts borrowed under the Avenue Capital Commitment bear interest at a variable rate per annum equal to the greater of (A) the Prime Rate plus five percent (5.00%) or (B) thirteen and one-half percent (13.50%). The loan required interest-only payments for the first 24 months through July 1, 2026, followed by equal monthly installments of principal plus accrued and unpaid interest until maturity, on July 1, 2027; provided, however that if the Company had drawn the full amount of Tranche 2 by December 31, 2025, and achieved for the trailing six month period ended September 30, 2026, at least $25 million of revenue, (the Interest only Milestone as defined in the Loan), the interest only period would have been extended by six months to January 1, 2027, followed by equal monthly installments of principal plus accrued and unpaid interest through January 1, 2028.

On November 13, 2025, the Company and Avenue Capital Group entered into the Amended Loan and Security Agreement, amending the Company's Loan and Security Agreement, dated June 28, 2024, as supplemented. The Amended Loan and Security Agreement funded an additional aggregate $2.5 million ("Tranche 2a") from Avenue Capital Group in November 2025 and provided an extension of the interest only period from July 1, 2026 to December 31, 2026, followed by equal monthly installments of principal plus accrued and unpaid interest until maturity on July 1, 2027. The Company would have access to an additional aggregate $2.5 million ("Tranche 2b") from Avenue Capital Group and receive a further six-month extension of the interest-only period to the July 1, 2027 maturity date subject to FDA approval of DrugSorb-ATR prior to December 31, 2026, which approval is now expected beyond this time frame. Tranche 2a and Tranche 2b, in the aggregate, replace Tranche 2 of the Avenue Capital Commitment. The Amended Loan and Security Agreement requires that the Company maintain revenue and certain operating cash burn targets (as defined in the Amended Loan and Security Agreement) prior to FDA approval of DrugSorb-ATR.

Under the terms of the Amended Loan and Security Agreement, we issued additional warrants to Avenue Capital Group to purchase 71,429 shares of the Company's common stock for cash at the exercise price of $14.00, which expire on November 13, 2030. The number of warrants and exercise price are fixed.

​

For further discussion regarding the Loan Agreement please see Note 6, "Long-Term Debt", to our Condensed Consolidated Financial Statements, included elsewhere in this Quarterly Report on Form 10-Q.

Rights Offering

On January 10, 2025, the Company closed the subscription period of its previously announced rights offering (the "Rights Offering"), raising aggregate gross proceeds of $6.25 million ($5.4 million net of fees) from the sale of all 312,500 Units reserved for the Rights Offering. Participants in the Rights Offering received Units, each Unit comprising of one share of common stock of the Company, one Series A Right Warrant to purchase one share of common stock with an expiration date of February 24, 2025, and one Series B Right Warrant to purchase one share of common stock with an expiration date of April 10, 2025. Up to an additional 312,500 shares of common stock were available for issuance upon exercise of the Right Warrants. Proceeds from the closing of the subscription period satisfied a debt covenant which allowed for $5 million of restricted cash on the Company's consolidated balance sheets to become unrestricted, and available for use. On February 24, 2025, approximately 70,860 Series A Right Warrants were exercised by holders, including members of management and the Board of Directors, at an exercise price of $22.60 per warrant, providing an additional $1.6 million in aggregate gross proceeds ($1.4 million net of fees). On April 4, 2025, the Board of Directors extended the expiration date of the Series B Right Warrants from April 10, 2025 to June 10, 2025. On June 11, 2025, the 5-day volume weighted average price of Common Stock over the last five-trading days prior to June 10, 2025 was lower than the minimum required price of $40.00 and, as a result, the Series B Right Warrants issued in connection with the previously announced Rights Offering expired worthless pursuant to their terms.

Technology Business Tax Certificate Program

In March 2026, we further supplemented our cash balance with the receipt of $0.4 million from the sale of our 2024 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).

Resource Allocation and Path to Cash-Flow Profitability

We have strategically managed our resources with a focus on driving commercial success, investing in key areas such as our regulatory submissions of DrugSorb-ATR and the development of clinical data, while also driving improved efficiencies and operating margins. Further, during the fourth quarter of 2025 and into the second quarter of fiscal 2026, the Company initiated the Strategic Workforce and Cost Reduction Plan to reduce costs, optimize operations, and accelerate a path to cash-flow profitability. These initiatives followed a comprehensive review of the Company's cost structure and operating model. This year long effort focused on disciplined execution allowed us to reduce our workforce by approximately 24%, while driving improved efficiencies and lower cost across the organization resulting in significant improvement in our operating results including an increase in gross margins to 75% and a 59% improvement in operating income for the three months ended September 30, 2026.As a result, the Company achieved its goal of operating cash flow breakeven in the three months ended September 30, 2026, excluding restructuring payments of $0.2 million. Our focus now turns to sustaining operating cash flow breakeven. Quarterly results can fluctuate with the timing of revenue, collections, and working capital, but we intend to manage the business to remain at or near operating cash flow breakeven while making targeted investments to support growth.

As of September 30, 2026, we had approximately $5.7 million in cash, including approximately $4.2 million in unrestricted cash and cash equivalents and $1.5 million of non-current restricted cash which may not be sufficient to fund the Company's operations beyond the next twelve months from the issuance of these condensed consolidated financial statements. These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.

​

Our expected future capital requirements may depend on many factors, including our ability to continue to drive efficiencies and remain at or near operating cash flow breakeven, while, expanding our customer base and sales force, and the timing and extent of spending in obtaining regulatory approval and introduction of new products, including the potential regulatory approval and introduction of DrugSorb-ATR in the United States. Additional sources of liquidity available to us include the 2024 Shelf, other public or private equity offerings, debt financing or from other sources. The sale of additional equity may result in dilution to our shareholders. There is no assurance that we will be able to secure funding on terms acceptable to us, or at all. Although the Company has taken actions to achieve cash flow breakeven, if it does not maintain operating cash flow breakeven, the potential increased need for capital could also make it more difficult to obtain funding through either equity or debt. Should additional capital not become available to us as needed, we may be required to take certain actions, such as slowing sales and marketing expansion, delaying further regulatory approvals, or further reducing headcount. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company routinely evaluates other financing sources, including less or non-dilutive debt financing, additional grant funding, royalty financing, strategic or direct investments, sales or licensing of assets, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors.

Critical Accounting Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions based on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Our actual results could differ from these estimates under different assumptions or conditions. Refer to "Critical Accounting Estimates" contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2025 for a complete discussion of our critical accounting estimates. There have been no material changes to our critical accounting estimates since our Annual Report on Form 10-K for the year ended December 31, 2025.

​

CytoSorbents Corporation published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 19, 2026 at 12:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]